“…This may be a reason why pH capsule investigations of patients with IBD gave mixed results [118,127,202]. Polymorphisms in SLC26A3 have been associated with either an increased incidence of IBD [9,51,150] or have been associated with response to therapy [8,17,188]. Therefore, intense research has been ongoing to elucidate the potential role of SLC26A3 in mucosal protection, as mentioned above, and in the maintenance of barrier properties [19,81].…”